Clinical TrialJun 24, 2026, 06:31 AM
Absci ABS-201 Phase 1 shows favorable safety, long half-life
AI Summary
Absci Corporation reported positive interim Phase 1 data for its investigational anti-prolactin receptor antibody, ABS-201, for androgenetic alopecia (AGA). The study medication was well tolerated with favorable safety data across all blinded single ascending dose (SAD) cohorts, and no serious adverse events were reported. An estimated half-life of at least 65 days supports a potential dosing interval of two or three injections over a six-month period. The company has initiated the multiple ascending dose (MAD) portion of the trial and anticipates interim proof-of-concept data in the second half of 2026.
Key Highlights
- ABS-201 Phase 1 interim data showed favorable safety and tolerability.
- Estimated half-life of ABS-201 is at least 65 days, supporting less frequent dosing.
- Multiple Ascending Dose (MAD) portion of HEADLINE trial initiated for AGA participants.
- No serious adverse events reported in single ascending dose (SAD) cohorts.
- All treatment-emergent adverse events (TEAEs) were mild, except one moderate headache.
- Interim proof-of-concept data for ABS-201 anticipated in H2 2026.
- Full proof-of-concept data for ABS-201 expected in early 2027.
- Phase 2 trial for endometriosis planned for initiation later this year.
Price Impact
More from ABSI